-
JGCA 2025 | Professor Bo Wei: Two Key Future Directions for Neoadjuvant Therapy in Locally Advanced Gastric Cancer—“Precision and Minimally Invasive Approaches”
From March 12 to 14, 2025, the 97th Annual Meeting of the Japanese Gastric Cancer Association (JGCA 2025) was held at the Nagoya Congress Center, bringing together leading experts from Japan and across the globe to exchange insights on the latest advancements in gastric cancer prevention and treatment. The event also spotlighted the application and…
-
JGCA 2025 | Professor Yanbing Zhou: Robot-Assisted Surgery Significantly Improves Clinical Outcomes for Obese Gastric Cancer Patients (Part 2)
3. Robotic Gastrectomy: More Suitable for Viscerally Obese Gastric Cancer Patients Obesity and metabolic syndrome in gastric cancer patients have become a pressing clinical issue. As global obesity rates continue…
-
Professor Chaoxu Zheng: Non-Invasive, Painless Surgery That Preserves Dignity—The Ultimate Goal in Colorectal Cancer Surgery | Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee
From February 28 to March 1, 2025, the 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee was held in Beijing. This year’s meeting focused on the standardization, precision, and personalization of colorectal cancer diagnosis and treatment, drawing top experts from China and around the world to explore the latest advances in…
-
JGCA 2025 | Professor Yanbing Zhou : How Minimally Invasive Techniques and Innovative Thinking Are Reshaping the Future of Gastric Cancer Treatment
1. Robotic Gastrectomy Poised to Enhance Clinical Outcomes in Gastric Cancer Patients Undergoing Neoadjuvant Therapy This year’s International Session at the JGCA 2025—titled “Current Status and Perspectives of Digital Innovation…
-
JGCA 2025 | Professors Bo Wei & Zekuan Xu: Proteomic Analysis Ushers in a New Era of Precision Therapy in Gastric Cancer
A study from the Chinese PLA General Hospital—focused on predicting the efficacy of neoadjuvant chemoimmunotherapy in gastric cancer using proteomic analysis—was selected for oral presentation (MO8-7) at the conference. Oncology…
-
Darolutamide vs Capecitabine in AR-Positive TNBC: UCBG 3-06 START Trial Results
On March 2025, The Lancet Oncology published results from the UCBG 3-06 START phase 2 trial, comparing darolutamide and capecitabine in patients with triple-negative, androgen receptor-positive (AR+) advanced breast cancer.Although…
-
TILs Predict Long-Term Survival in HER2+ Breast Cancer: 10-Year ShortHER Trial Insights
A decade after the start of the ShortHER trial, new data published in JAMA Oncology sheds light on how tumor-infiltrating lymphocytes (TILs) can guide treatment decisions in early ERBB2-positive (HER2+)…
-
Neoadjuvant Nivolumab Boosts pCR in High-Risk ER+/HER2− Breast Cancer
In a landmark phase 3 trial published in Nature Medicine, Prof. Sherene Loi and colleagues investigated whether immunotherapy can shift the treatment paradigm in high-risk early ER+/HER2− breast cancer.The study…
Connecting Medical Expertise through Media